Grati Francesca Romana, Molina Gomes Denise, Ferreira Jose Carlos Pinto B, Dupont Celine, Alesi Viola, Gouas Laetitia, Horelli-Kuitunen Nina, Choy Kwong Wai, García-Herrero Sandra, de la Vega Alberto Gonzalez, Piotrowski Krzysztof, Genesio Rita, Queipo Gloria, Malvestiti Barbara, Hervé Bérénice, Benzacken Brigitte, Novelli Antonio, Vago Philippe, Piippo Kirsi, Leung Tak Yeung, Maggi Federico, Quibel Thibault, Tabet Anne Claude, Simoni Giuseppe, Vialard François
TOMA Advanced Biomedical Assays S.p.A, Busto Arsizio, Italy.
CHI Poissy St Germain, Département de Cytogénétique, Obstétrique et Gynécologie, Poissy, France.
Prenat Diagn. 2015 Aug;35(8):801-9. doi: 10.1002/pd.4613. Epub 2015 Jun 24.
The implementation of chromosomal microarray analysis (CMA) in prenatal testing for all patients has not achieved a consensus. Technical alternatives such as Prenatal BACs-on-Beads(TM) (PNBoBs(TM) ) have thus been applied. The aim of this study was to provide the frequencies of the submicroscopic defects detectable by PNBoBs(TM) under different prenatal indications.
A total of 9648 prenatal samples were prospectively analyzed by karyotyping plus PNBoBs(TM) and classified by prenatal indication. The frequencies of the genomic defects and their 95%CIs were calculated for each indication.
The overall incidence of cryptic imbalances was 0.7%. The majority involved the DiGeorge syndrome critical region (DGS). The additional diagnostic yield of PNBoBs(TM) in the population with a low a priori risk was 1/298. The prevalences of DGS microdeletion and microduplication in the low-risk population were 1/992 and 1/850, respectively.
The constant a priori risk for common pathogenic cryptic imbalances detected by this technology is estimated to be ~0.3%. A prevalence higher than that previously estimated was found for the 22q11.2 microdeletion. Their frequencies were independent of maternal age. These data have implications for cell-free DNA screening tests design and justify prenatal screening for 22q11 deletion, as early recognition of DGS improves its prognosis.
对所有患者在产前检测中实施染色体微阵列分析(CMA)尚未达成共识。因此,已应用诸如产前珠上细菌人工染色体(PNBoBs)等技术替代方法。本研究的目的是提供在不同产前指征下PNBoBs可检测到的亚微观缺陷的频率。
对9648份产前样本进行核型分析加PNBoBs前瞻性分析,并按产前指征分类。计算每种指征下基因组缺陷的频率及其95%置信区间。
隐匿性失衡的总体发生率为0.7%。大多数涉及迪乔治综合征关键区域(DGS)。在先天风险较低的人群中,PNBoBs的额外诊断率为1/298。低风险人群中DGS微缺失和微重复的患病率分别为1/992和1/850。
该技术检测到的常见致病性隐匿性失衡的恒定先天风险估计约为0.3%。发现22q11.2微缺失的患病率高于先前估计。其频率与母亲年龄无关。这些数据对游离DNA筛查试验设计有影响,并证明对22q11缺失进行产前筛查是合理的,因为早期识别DGS可改善其预后。